Switch theme
Sign up to access all valuation multiples
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. It has two geographic segments Europe/Asia and USA. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities.
1971
2.2K+
LTM Revenue $717M
LTM EBITDA $209M
$3.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bachem has a last 12-month revenue of $717M and a last 12-month EBITDA of $209M.
In the most recent fiscal year, Bachem achieved revenue of $684M and an EBITDA of $202M.
Bachem expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bachem valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $653M | $684M | XXX | XXX | XXX |
| Gross Profit | $194M | $200M | XXX | XXX | XXX |
| Gross Margin | 30% | 29% | XXX | XXX | XXX |
| EBITDA | $192M | $202M | XXX | XXX | XXX |
| EBITDA Margin | 29% | 29% | XXX | XXX | XXX |
| Net Profit | $114M | $126M | XXX | XXX | XXX |
| Net Margin | 17% | 18% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bachem's stock price is CHF 48 (or $54).
Bachem has current market cap of CHF 3.6B (or $4.0B), and EV of CHF 3.5B (or $3.9B).
See Bachem trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.9B | $4.0B | XXX | XXX | XXX | XXX | $1.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bachem has market cap of $4.0B and EV of $3.9B.
Bachem's trades at 5.5x LTM EV/Revenue multiple, and 18.8x LTM EBITDA.
Analysts estimate Bachem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bachem and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.9B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 19.4x | XXX | XXX | XXX |
| P/E | 29.7x | XXX | XXX | XXX |
| P/E/Growth | 1.4x | XXX | XXX | XXX |
| EV/FCF | -25.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBachem's NTM/LTM revenue growth is 23%
Bachem's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $25K for the same period.
Over next 12 months, Bachem's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bachem's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bachem and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 52% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $25K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 8% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Borouge | XXX | XXX | XXX | XXX | XXX | XXX |
| Fertiglobe | XXX | XXX | XXX | XXX | XXX | XXX |
| Akzo Nobel | XXX | XXX | XXX | XXX | XXX | XXX |
| Avantium | XXX | XXX | XXX | XXX | XXX | XXX |
| DSM Firmenich | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bachem acquired XXX companies to date.
Last acquisition by Bachem was XXXXXXXX, XXXXX XXXXX XXXXXX . Bachem acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bachem founded? | Bachem was founded in 1971. |
| Where is Bachem headquartered? | Bachem is headquartered in Switzerland. |
| How many employees does Bachem have? | As of today, Bachem has 2.2K+ employees. |
| Is Bachem publicy listed? | Yes, Bachem is a public company listed on SWX. |
| What is the stock symbol of Bachem? | Bachem trades under BANB ticker. |
| When did Bachem go public? | Bachem went public in 2001. |
| Who are competitors of Bachem? | Similar companies to Bachem include e.g. Borouge, Fertiglobe, Akzo Nobel, Avantium. |
| What is the current market cap of Bachem? | Bachem's current market cap is $4.0B |
| What is the current revenue of Bachem? | Bachem's last 12-month revenue is $717M. |
| What is the current EBITDA of Bachem? | Bachem's last 12-month EBITDA is $209M. |
| What is the current EV/Revenue multiple of Bachem? | Current revenue multiple of Bachem is 5.5x. |
| What is the current EV/EBITDA multiple of Bachem? | Current EBITDA multiple of Bachem is 18.8x. |
| What is the current revenue growth of Bachem? | Bachem revenue growth between 2023 and 2024 was 5%. |
| Is Bachem profitable? | Yes, Bachem is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
